Skip to main content
SpringerLink
Log in

Rivaroxaban: no reduction in death rate or increase in major bleeding

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Medically Ill Patient Assessment of Rivaroxaban versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk

  2. dosage adjusted in patients with renal failure

References

  1. Spyropoulos AC, et al. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. New England Journal of Medicine : 26 Aug 2018. Available from: URL: http://doi.oeg/10.1056/NEJMoa1805090.

  2. Zannad F, et al. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. New England Journal of Medicine : 27 Aug 2018. Available from: URL: http://doi.org/10.1056/NEJMoa1808848.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rivaroxaban: no reduction in death rate or increase in major bleeding. Reactions Weekly 1719, 12 (2018). https://doi.org/10.1007/s40278-018-51567-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-51567-6

Search

Navigation